NDAQ — Nasdaq, Inc.

Sentiment is genuinely split, and the split is the story. Sell-side is constructive: a 'Buy' consensus with 22 buys against 1 sell, a $113.40 average price target versus a $91.19 spot price as of 2026-09-13, and headlines that are hard to beat — a $100M Nasdaq Ventures investment into Payward/Kraken for tokenized equities (announced 2026-09-10), Nasdaq selected as Anthropic's IPO venue (2026-09-13) following SpaceX earlier in the summer, and a Q2 2026 beat with full-year guidance raised. Institutional 13F flow shows accumulation. But price is voting differently: -5.87% in one week and -4.67% in one month into 2026-09-13, with RSI at 35.39 and price 5.9% under its 20-day average. Nothing in the brief is company-specific bad news, so the selling reads as macro-driven multiple compression (rising Treasury yields, oil above $92 on U.S.–Iran tension) rather than a change in the earnings story. When narrative and tape disagree this sharply, 'Neutral' is the honest label.

Revenue stepped from $1.451B in Q3 2023 to a record $2.532B in Q2 2026, but the year-over-year path is lumpy and partly distorted by the Adenza consolidation: +23.3% (Q4 2024), +24.9% (Q1 2025), then a hard deceleration to +2.9% (Q3 2025), +2.5% (Q4 2025) and +2.2% (Q1 2026), followed by a re-acceleration to +21.1% in Q2 2026 — a +18.5% sequential jump off Q1 2026's $2.137B. That Q2 2026 inflection looks real rather than noise (it lines up with the brief's 'record Q2 net revenue' and an IPO-heavy summer), though the FMP revenue level conflicts with the brief's $1.5B reference, so treat the magnitude with caution. The much cleaner and more important signal is margin: operating margin climbed from 21.4% in Q4 2023 to 25.5% (Q4 2024), 30.3% (Q4 2025) and 34.6% in Q2 2026 — roughly 1,300bp of expansion over ten quarters, driven by Adenza cost synergies and operating leverage on a largely fixed-cost exchange/data base. That is structural, not a blip. GAAP diluted EPS moved from $0.61 (Q4 2024) to $0.90 (Q4 2025) to $0.91 (Q1 2026) to $0.89 (Q2 2026); the flat Q2 EPS despite $877M of operating income versus $657M in Q1 points to a below-the-line item (tax/other), not operating deterioration — the brief's non-GAAP EPS of $1.07 on the same quarter confirms the operating engine was strong. Verdict: margins and cash flow inflecting up, revenue growth lumpy but re-accelerating.

Fair, leaning mildly cheap on forward earnings. As of 2026-09-13, NDAQ traded at 26.28x trailing GAAP EPS of $3.488 versus a five-year average P/E of 30.98x, and roughly 22.1x the $4.129 next-FY consensus EPS — a 15% to 29% discount to its own history depending on which base you use. PEG of 0.823 is comfortably below 1. The offset is on the top line: P/S of 5.854 is slightly above the 5.68 five-year average, EV/EBITDA is ~19x, and the free cash flow yield is only ~3.8% ($1.951B TTM FCF on a $51.0B market cap), which is not cheap for a business whose organic revenue growth is mid-single-digit. Net call: not expensive, not a bargain — a fair multiple on a good, capital-light franchise with an earnings-based discount to its own history.

At $91.19 on 2026-09-13, the market is paying ~22x forward EPS for a company that just printed a 34.6% operating margin and raised guidance — i.e., a stock priced for mid-single-digit growth, not for the re-acceleration the Q2 2026 numbers showed. Critically, the recent 5.87% weekly drop was not estimate-driven: nothing in the brief implies negative revisions, so this is multiple compression from the macro tape, not the earnings line breaking. That creates an asymmetry into Q3 2026 (late October): if the raised $2.530–2.570B opex guide turns out to be investment spending that still converts, the multiple has room to normalize back toward the high-20s and the $100+ zone opens up. If instead the cost increase is the leading edge of structural expense inflation, EPS estimates — not the multiple — become the thing that breaks. Also watch the GAAP/non-GAAP spread: $0.89 GAAP versus $1.07 non-GAAP in Q2 2026 means the ~26x headline screen overstates how expensive the cash economics actually are.

As of 2026-09-13, NDAQ's RSI(14) stood at 35.39 — weak, near-but-not-at oversold — with price 5.9% below its 20-day SMA (implied ~$96.91), 2.86% below its 50-day (~$93.87), and only 0.74% above its 200-day (~$90.52). That is a short-term downtrend inside a still-intact long-term uptrend, with the 200-day sitting almost exactly at the current quote and acting as the line that matters most. Against the 52-week range of $76.55–$101.79, the stock is 10.4% off its high and 19% off its low. Entry-timing implication: this is a defensible zone to begin scaling in near a rising 200-day with RSI sub-40, but there is no reversal confirmation yet — a decisive weekly close below roughly $90.50 would open the low- to mid-$80s and argue for patience rather than adding.

• Rates and geopolitics: rising Treasury yields and oil above $92 on U.S.–Iran tension are compressing multiples across high-quality financials and cooling risk appetite for new issuance — the most plausible driver of the 5.87% weekly decline into 2026-09-13, since nothing company-specific broke.
• Secular mix shift: steady migration of asset managers to recurring SaaS compliance and anti-financial-crime software (Verafin, Adenza) reduces NDAQ's dependence on trading-volume cyclicality and supports a structurally higher multiple than a pure exchange.
• Market-structure regulation: the 23/5 extended-trading launch on December 6, 2026 is a real revenue opportunity but invites regulator and incumbent-venue scrutiny; a European financial transaction tax remains a live regional headwind.
• IPO cycle strength: SpaceX's summer listing and the Anthropic selection show the equity capital markets window is genuinely open, lifting listing fees and the Nasdaq-100/index-data franchise — but this is inherently cyclical revenue that can shut quickly.
• Tokenization and crypto policy: the $100M Payward (Kraken) investment and Nasdaq Equity Tokens are a real option on always-on market infrastructure, but their value is entirely contingent on a still-forming U.S. regulatory framework.

• Q3 2026 earnings in late October 2026 — the first clean read on whether ~12% SaaS ARR growth and the raised $2.530–2.570B opex guidance are compatible with continued margin expansion, plus an update on the variable accelerated share repurchase program.
• December 6, 2026 launch of the 23/5 extended trading architecture — the largest identifiable structural revenue opportunity on the near-term calendar.
• Anthropic's IPO (venue selected 2026-09-13) and the broader listing pipeline after SpaceX — high-visibility listing-fee and index-inclusion revenue.
• Tokenized equities build-out with Payward/Kraken (Nasdaq Equity Tokens), backed by the September 10, 2026 $100M Nasdaq Ventures commitment.
• Any easing in Treasury yields or a broadening 2027 IPO calendar, which would re-rate the multiple faster than earnings alone could.

• Leverage: $8.492B of long-term debt against only $0.520B of cash (net debt ~$8.0B, roughly 4x TTM free cash flow) makes interest expense a direct EPS drag if yields stay high through the next refinancing window.
• Weak returns on capital: ROIC of 8.3% against ROE of 14.6% shows the goodwill-heavy Adenza purchase is not yet earning a wide spread over cost of capital, which caps how much quality premium the multiple deserves.
• Cost guidance was raised to $2.530–2.570B for FY2026 on heavy IPO and compensation activity; if those costs persist without matching revenue, the margin expansion story — the single best part of the equity case — stalls.
• Cyclicality hiding inside a 'defensive' franchise: the 34.6% Q2 2026 operating margin was flattered by an unusually strong listings/transaction quarter, and listing revenue can evaporate if the IPO window shuts.
• Insider selling: $86.7M sold versus $21.7M bought over the trailing twelve months, a modest but consistent negative signal against the bullish sell-side consensus.
• Regulatory risk across three fronts at once: European financial transaction tax proposals, unclear tokenization rules, and market-structure scrutiny of 24/5-style extended trading.

NDAQ at $91.19 on 2026-09-13 is a reasonable, not exceptional, entry into a genuinely high-quality, capital-light, recurring-revenue-heavy franchise. The business is executing — record Q2 2026 revenue, operating margin up from ~21% to 34.6% over ten quarters, free cash flow of $1.951B that exceeds reported net income (accruals ratio of -0.75%, i.e. cash-backed earnings), guidance raised, and a listing pipeline that includes SpaceX and Anthropic — while the shares trade 10% below their high at 22x forward EPS versus a 31x five-year average. The offsets are real: $8.0B of net debt, an 8.3% ROIC that barely clears cost of capital, genuinely mid-single-digit organic growth, and a Q2 margin flattered by a hot capital-markets quarter. My fair value work lands near $100, implying high-single-digit upside plus a 1.27% dividend — a decent risk/reward, not a table-pounding one. This is analysis, not personalized financial advice.

Method: a 50/50 blend of two anchors, both as of 2026-09-13. (1) A justified forward P/E of 24x — below the 31.0x five-year average, appropriate for a low-double-digit EPS grower with high recurring revenue — applied to the $4.129 next-FY consensus EPS gives $99.10. (2) A two-stage DCF on TTM free cash flow of $1.951B growing 9% for ten years with 3% terminal growth and an 8% WACC, net of $7.97B net debt and 559M shares, gives ~$101.30. The two land within $2 of each other at ~$100. I deliberately lean on GAAP-based earnings and actual cash flow: the ~$0.18/quarter Adenza amortization gap (GAAP $0.89 vs non-GAAP $1.07 in Q2 2026) is precisely what separates my number from the $113.40 street target — applying 24x to a non-GAAP forward EPS of ~$4.65 would produce ~$112 — and I treat that amortization as a real cost of the acquisition rather than ignoring it.